Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
1-year Mortality
9%
14-day Mortality
15%
30-day Mortality
14%
95% Confidence Interval
13%
Acinetobacter Baumannii (A. baumannii)
12%
Acute Hospital
8%
Antimicrobial Resistance
14%
Bacteremia
28%
Bloodstream Infection
45%
Carbapenem Resistance
16%
Carbapenem-resistant Acinetobacter Baumannii
76%
Carbapenem-resistant Acinetobacter Baumannii Infection
12%
Carbapenem-resistant Enterobacterales
20%
Carbapenemase
18%
Carbapenemase-producing Enterobacterales
24%
Carbapenemases
16%
Case Fatality Rate
15%
Ceftazidime-avibactam
11%
Clinical Failure
13%
Colistin
43%
Colistin-meropenem
15%
Colorectal Surgery
14%
Combination Therapy
23%
COVID-19
25%
Enterobacterales
14%
Enterobacteriaceae
9%
Ertapenem
14%
ESBL-PE
14%
Escherichia Coli
35%
Healthcare Workers
18%
Hospital-onset
12%
Hospitalized Patients
17%
Human Adenovirus Type 55
14%
Human Infection
14%
In Vivo Fitness
14%
Infection Rate
8%
Israel
85%
Israeli
22%
Monotherapy
18%
Multidrug-resistant Gram-negative Bacteria
16%
Murine Model
14%
National Cohort Study
22%
Population-based Study
8%
Quick Sequential Organ Failure Assessment (qSOFA)
10%
Randomized Controlled Trial
16%
Retrospective Cohort Study
26%
Sentinel
13%
Severe Infection
10%
Staphylococcus
10%
Third-generation Cephalosporin-resistant
8%
Pharmacology, Toxicology and Pharmaceutical Science
Acinetobacter Baumannii
44%
Acinetobacter Infection
8%
Adenoviridae
7%
Antibiotics
14%
Antimicrobial Agent
25%
Asthma
7%
Bacterial Infection
8%
Bacterium
15%
Beta Lactam
7%
Beta Lactamase Inhibitor
7%
Bloodstream Infection
67%
Carbapenem
100%
Carbapenemase
9%
Case-Control Study
7%
Cefiderocol
7%
Cefuroxime
7%
Clinical Study
7%
Cohort Study
7%
Colistimethate
63%
Combination Therapy
19%
Coronavirinae
7%
Diseases
12%
Enterobacteriaceae
8%
Ertapenem
14%
Escherichia coli
16%
Extended Spectrum Beta Lactamase
13%
Gram Negative Bacterium
27%
Gram Negative Infection
17%
Infection
53%
Infectious Agent
8%
Influenza
7%
Medical Cannabis
7%
Meropenem
34%
Metronidazole
8%
Monotherapy
16%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
7%
Ovary Cancer
7%
Penicillinase
8%
Pharmacokinetics
8%
Pneumonia
6%
Prospective Study
7%
Randomized Clinical Trial
9%
Randomized Controlled Trial
25%
Salicylate Sodium
7%
Staphylococcus Aureus
8%
Surgical Infection
8%
Synergism
7%
Third Generation Cephalosporin
9%
Thrombocytosis
7%
Vaccination
7%
Medicine and Dentistry
Acinetobacter Baumannii
26%
Adenoviridae
7%
Antibiotic Prophylaxis
8%
Antibiotic Resistance
15%
Antibiotic Therapy
11%
Antibiotics
12%
Antimicrobial Stewardship
14%
Bacterial Infection
8%
Beta Lactamase Inhibitor
7%
Biological Marker
8%
Bloodstream Infection
45%
Carbapenem
54%
Cohort Studies
7%
Colectomy
9%
Colistimethate
23%
Colorectal Surgery
22%
Combination Therapy
9%
COVID-19
29%
Diabetic Retinopathy
7%
Diseases
7%
Ertapenem
14%
Escherichia coli
15%
Estriol
7%
Extended Spectrum Beta Lactamase
13%
Extended Spectrum Beta Lactamase Producing Enterobacteriaceae
8%
Gram-Negative Bacteria
28%
Gram-Negative Bacterial Infection
7%
Health Care Cost
9%
Health Care Personnel
11%
Infection
55%
Inflammation
8%
Intensive Care Unit
11%
Meropenem
15%
Metronidazole
8%
Oral
7%
PARP Inhibitor
7%
Pathogen
13%
Penicillinase
8%
Prospective Study
14%
Randomized Controlled Trial
23%
Retrospective Cohort Study
11%
Seroprevalence
7%
Severe Acute Respiratory Syndrome Coronavirus 2
8%
Solid Organ Transplantation
7%
Staphylococcus Aureus
8%
Subretinal Fluid
7%
Surgical Infection
16%
Systematic Review
7%
Third Generation Cephalosporin
9%
β-Lactamase inhibitor
7%